STAMPEDE Will 'Change Practice' in High-Risk Prostate Cancer— Trial showed adding abi to ADT improved metastasis-free and overall survival

[HopingForTheBest1]

See link to article below-

medpagetoday.com/meetingcov...

This trial looked at the M0 population -- high-risk M0 population, metastatic. High risk being defined as either node positive, or high-risk node-negative, which means T3-4 disease, PSA 40 or greater, or Gleason 8-10 grade group 4, essentially, or relapsing.

[HopingForTheBest1]

Unfortunately, my prior experience with abiraterone/prednisone and ADT was that abi failed to control my PSA rise after just 6 months of use,

[lewicki in reply to HopingForTheBest1]

Drug companies need more of it to be prescribed?

[Hidden in reply to lewicki]

Who cares....is it having a positive outcome? If you any doubts the outcome is legit, one can always do ADT alone.

[CAMPSOUPS in reply to lewicki]

NO they don't need more of it to be prescribed.The trial was done to help patients.

[GP24]

I think this group of patients will show metastases using a PSMA PET/CT. Then you could use Abiraterone, Enzalutamid(ARCHES/ENZAMET trials) and Apalutamide (TITAN trial). If not, surgery and radiation will be an option.

[Hidden]

Nice to see some study results for the M0 population. My MO treated me as if I was in this study..2yrs ADT + AAP. Hoping for alot longer than 6yrs MFS.

[lewicki in reply to Hidden]

Thanks . Great information.I went to Germany 30 months ago and had the PSMA scan and LU-177 and AC-225.

[lewicki in reply to Hidden]

Thanks. Great news.